Overdose of Mucorama in details
No specific overdose symptoms have been reported in man to date.
Based on accidental overdose and/or medication error reports the observed symptoms are consistent with the known side effects of Mucorama at recommended doses and may need symptomatic treatment.
Mucorama warnings
With caution used Mucorama Lark Laboratories when tachyarrhythmia and other cardiac arrhythmias, arterial hypertension, myocarditis, heart defects, aortic stenosis, diabetes, thyrotoxicosis, glaucoma, acute heart failure (with careful medical supervision).
Increase doses or frequency of receiving albuterol (salbutamol) should be under the supervision of a doctor. Reducing the interval may be only in exceptional cases and should be strictly justified.
In the application of salbutamol there was a risk of hypokalemia, so the period of treatment in patients with severe asthma should monitor the flow levels of potassium in the blood. The risk of hypokalemia increases with hypoxia.
Mucorama precautions
Mucorama 30-mg tablets contain lactose 684 mg per maximum recommended daily dose (120 mg). Patients with rare hereditary galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Mucorama.
Mucorama liquid (30 mg/5 mL) contains sorbitol 7.4 g per maximum recommended daily dose (20 mL). Patients with rare hereditary fructose intolerance should not take Mucorama.
There have been very few reports of severe skin lesions eg, Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) in temporal association with the administration of expectorants eg, Mucorama. Mostly these could be explained by the severity of the patient's underlying disease and/or concomitant medication. In addition during the early phase of a Stevens-Johnson syndrome or TEN, a patient may first experience non-specific influenza-like prodromes, it is possible that a symptomatic treatment is started with a cough and cold medication.
Therefore, if new skin or mucosal lesions occur, medical advice should be sought immediately and treatment with Mucorama discontinued as a precaution.
In the presence of impaired renal function, Mucorama may be used only after consulting a physician.
Effects on the Ability to Drive or Operate Machinery: There is no evidence for an effect on the ability to drive and use machines. Studies on the effects on the ability to drive and use machines have not been performed.
Use in pregnancy & lactation: Mucorama crosses the placental barrier. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Extensive clinical experience after the 28th week of pregnancy has shown no evidence of harmful effects on the foetus. Nonetheless, the usual precautions regarding the use of drugs during pregnancy should be observed. Especially during the 1st trimester, the use of Mucorama is not recommended.
Mucorama is excreted in breast milk. Therefore, Mucorama is not recommended for use in nursing mothers. However, unfavourable effects on breastfed infants would not be expected.
References
- DrugBank. "ambroxol". http://www.drugbank.ca/drugs/DB06742 (accessed September 17, 2018).
- MeSH. "Expectorants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- Burnham Center for Chemical Geno. "SID50085991: Aqueous solubility in buffer at pH 7.4". https://pubchem.ncbi.nlm.nih.gov/bio... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
